tiprankstipranks
Trending News
More News >
RAPT Therapeutics (RAPT)
NASDAQ:RAPT
Advertisement

RAPT Therapeutics (RAPT) AI Stock Analysis

Compare
377 Followers

Top Page

RAPT

RAPT Therapeutics

(NASDAQ:RAPT)

Rating:39Underperform
Price Target:
RAPT Therapeutics' overall stock score reflects significant challenges, primarily due to its inability to generate revenue and consistent operational losses. The strong equity position in the balance sheet is a positive, but technical indicators suggest a continued downward trend. The negative valuation metrics further highlight the risks associated with the stock.
Positive Factors
Drug Efficacy
RPT904 demonstrated a 60-day half-life at 150 mg vs 26 days for omalizumab at 150 mg, indicating potential for broader applicability and potential for at least comparable efficacy with less frequent dosing.
Financial Performance
RAPT reported better than expected net loss per share, which was ($0.08) versus the consensus of ($0.14).
Market Opportunity
Food Allergy is a massive market opportunity, and even an incremental share can result in a potentially large blockbuster opportunity for the company.
Negative Factors
Clinical Trials
A setback in the Jemincare’s phase 2 study in CSU and asthma could call into question the potential success of RPT904.
Data Timelines
The Neutral rating on RAPT shares balances the de-risked mechanism and significant potential of lead asset RPT904 in Food Allergy and Chronic Spontaneous Urticaria with prolonged timelines to company-sponsored data in key indications.
Market Sentiment
RAPT shares are likely to be a sentiment underperformer until RAPT flips its own cards for RPT904.

RAPT Therapeutics (RAPT) vs. SPDR S&P 500 ETF (SPY)

RAPT Therapeutics Business Overview & Revenue Model

Company DescriptionRAPT Therapeutics is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing oral small molecule therapies for oncology and inflammatory diseases. Based in the United States, RAPT employs its proprietary drug discovery and development engine to create highly selective oral therapies aimed at key points in the immune system. The company’s lead product candidates include RPT193 and FLX475, which are designed to target specific pathways involved in the regulation of immune cells.
How the Company Makes MoneyRAPT Therapeutics generates revenue primarily through strategic collaborations and partnerships with other pharmaceutical companies, as well as government grants and funding for its research initiatives. The company may also license its proprietary technology and intellectual property to other firms, providing another revenue stream. As RAPT advances its product candidates through clinical trials and towards potential commercialization, it anticipates generating revenue from the sale of its therapies upon obtaining necessary regulatory approvals.

RAPT Therapeutics Financial Statement Overview

Summary
RAPT Therapeutics faces significant challenges, primarily due to its inability to generate revenue and consistent operating losses. While the balance sheet shows a strong equity base and low leverage, the company's cash flow and income statement highlight sustainability concerns.
Income Statement
20
Very Negative
RAPT Therapeutics has consistently reported negative net income and EBIT over the past years, indicating ongoing operational challenges. The company has not generated any revenue in recent years, which is a concern for sustainability. The lack of revenue and consistent losses contribute to a low score for the income statement.
Balance Sheet
55
Neutral
The balance sheet shows a relatively strong equity position with a low debt-to-equity ratio, indicating conservative leverage. However, the lack of revenue generation poses a risk to the sustainability of the company's financial health. The equity ratio is high, showing a solid capital structure, but the ongoing losses are a concern.
Cash Flow
30
Negative
The company has consistently reported negative operating and free cash flows, pointing to challenges in generating cash from operations. The reliance on financing activities to support cash flow needs is notable. Despite this, the company has maintained a healthy cash position, mitigating some risk.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue0.000.001.53M3.81M5.04M
Gross Profit0.00-3.55M-1.28M2.82M5.04M
EBITDA-126.33M-125.85M-84.75M-68.21M-52.09M
Net Income-129.87M-116.80M-81.88M-68.21M-52.89M
Balance Sheet
Total Assets240.32M173.33M266.21M198.64M118.97M
Cash, Cash Equivalents and Short-Term Investments231.06M158.86M249.07M189.65M111.51M
Total Debt4.49M6.91M8.99M0.000.00
Total Liabilities50.42M26.29M21.04M12.26M14.79M
Stockholders Equity189.90M147.03M245.17M186.38M104.18M
Cash Flow
Free Cash Flow-83.42M-98.17M-71.62M-61.78M-40.89M
Operating Cash Flow-83.30M-97.05M-70.77M-61.03M-40.49M
Investing Cash Flow52.70M104.13M-45.49M-81.35M-87.44M
Financing Cash Flow152.85M1.45M131.18M141.48M75.46M

RAPT Therapeutics Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price10.80
Price Trends
50DMA
9.14
Positive
100DMA
8.60
Positive
200DMA
9.90
Positive
Market Momentum
MACD
0.93
Positive
RSI
52.02
Neutral
STOCH
22.33
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RAPT, the sentiment is Neutral. The current price of 10.8 is above the 20-day moving average (MA) of 10.59, above the 50-day MA of 9.14, and above the 200-day MA of 9.90, indicating a bullish trend. The MACD of 0.93 indicates Positive momentum. The RSI at 52.02 is Neutral, neither overbought nor oversold. The STOCH value of 22.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for RAPT.

RAPT Therapeutics Risk Analysis

RAPT Therapeutics disclosed 66 risk factors in its most recent earnings report. RAPT Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

RAPT Therapeutics Peers Comparison

Overall Rating
UnderperformOutperform
Sector (61)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
61
Neutral
HK$17.40B5.81-7.44%3.53%11.55%-28.15%
55
Neutral
$124.75M-24.73%-1.02%-8.59%
54
Neutral
$138.40M87.50-24.22%-23.40%17.80%
53
Neutral
$274.72M123.38%10.49%47.31%
39
Underperform
$153.98M-26.10%30.76%
39
Underperform
$178.59M-75.60%-2.29%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
RAPT
RAPT Therapeutics
10.80
-12.88
-54.39%
CGEN
Compugen
1.45
-0.30
-17.14%
ADCT
ADC Therapeutics
2.77
-0.11
-3.82%
NKTX
Nkarta
2.17
-3.80
-63.65%
SEER
Seer
2.12
0.28
15.22%

RAPT Therapeutics Corporate Events

Executive/Board ChangesShareholder Meetings
RAPT Therapeutics Announces Board Restructuring in 2025
Neutral
Mar 27, 2025

On March 21, 2025, Dr. Wendye R. Robbins informed RAPT Therapeutics’ Board of Directors that she will not seek re-election at the company’s 2025 annual meeting, marking the end of her tenure. Subsequently, on March 25, 2025, the Board decided to reduce its size from six to five members, effective at the annual meeting.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Apr 22, 2025